Compare PSMT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSMT | ORKA |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Department/Specialty Retail Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.4B |
| IPO Year | 2005 | N/A |
| Metric | PSMT | ORKA |
|---|---|---|
| Price | $196.08 | $87.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $92.50 |
| AVG Volume (30 Days) | 248.3K | ★ 1.3M |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 5.47 | N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $4,066,093,000.00 | N/A |
| Revenue This Year | $12.29 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | $67.35 | ★ N/A |
| Revenue Growth | ★ 12.33 | N/A |
| 52 Week Low | $101.36 | $10.97 |
| 52 Week High | $196.08 | $91.00 |
| Indicator | PSMT | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 81.03 | 73.57 |
| Support Level | $120.37 | $27.81 |
| Resistance Level | N/A | $91.00 |
| Average True Range (ATR) | 4.92 | 4.74 |
| MACD | 1.35 | 2.27 |
| Stochastic Oscillator | 95.63 | 93.72 |
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.